Von dem Buch The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (McFarland Health Topics) haben wir 2 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: Elaine A. Moore, Dr. Yash P. Agrawal, Samantha Wilkinson, Dr. Yash P. Agrawal, Samantha Wilkinson, Foreword: Dr. Yash P. Agrawal, Collaborator: Samantha Wilkinson: The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (McFarland Health Topics) (ISBN: 9780786452583) 2008, in Englisch, auch als eBook.Nur diese Ausgabe anzeigen…
100%: Moore, Elaine A./ Wilkinson, Samantha/ Agrawal, Yash Pal, M.D., Ph.D. (Foreward By): The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (Paperback) (ISBN: 9780786437153) in Englisch, Taschenbuch.Nur diese Ausgabe anzeigen…
The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (McFarland Health Topics)
10 Angebote vergleichen
| Preise | 2013 | 2014 | 2015 |
|---|---|---|---|
| Schnitt | € 17,01 | € 18,47 | € 22,23 |
| Nachfrage |
1
Symbolbild
The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (Paperback) (1984)
EN PB NWISBN: 9780786437153 bzw. 0786437154, in Englisch, McFarland & Company, Vereinigte Staaten von Amerika, Taschenbuch, neu.
Lieferung aus: Vereinigte Staaten von Amerika, Versandkostenfrei.
Von Händler/Antiquariat, Grand Eagle Retail [50531827], Romulus, MI, U.S.A.
Paperback. Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much lower doses in.Shipping may be from multiple locations in the US or from the UK, depending on stock availability. 213 pages. 0.340.
Von Händler/Antiquariat, Grand Eagle Retail [50531827], Romulus, MI, U.S.A.
Paperback. Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much lower doses in.Shipping may be from multiple locations in the US or from the UK, depending on stock availability. 213 pages. 0.340.
2
Symbolbild
The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (Paperback) (2008)
EN PB NWISBN: 9780786437153 bzw. 0786437154, in Englisch, McFarland & Company, Vereinigte Staaten von Amerika, Taschenbuch, neu.
Von Händler/Antiquariat, AussieBookSeller [52402892], Artarmon, NSW, Australia.
Paperback. Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much l.Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. 213 pages. 0.340.
Paperback. Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much l.Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. 213 pages. 0.340.
3
The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (2008)
EN PB USISBN: 9780786437153 bzw. 0786437154, in Englisch, 223 Seiten, McFarland, Taschenbuch, gebraucht.
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 1-2 business days.
Von Händler/Antiquariat, O-BOOKS.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers. Paperback, Label: McFarland, McFarland, Produktgruppe: Book, Publiziert: 2008-12-01, Studio: McFarland, Verkaufsrang: 116230.
Von Händler/Antiquariat, O-BOOKS.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers. Paperback, Label: McFarland, McFarland, Produktgruppe: Book, Publiziert: 2008-12-01, Studio: McFarland, Verkaufsrang: 116230.
4
The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders
EN NW EB DLISBN: 9780786452583 bzw. 0786452587, in Englisch, McFarland & Company, Incorporated Publishers, McFarland & Company, Incorporated Publishers, McFarland & Company, Incorporated Publishers, neu, E-Book, elektronischer Download.
Lieferung aus: Vereinigte Staaten von Amerika, zzgl. Versandkosten, Free Shipping on eligible orders over $25, in-stock.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.
5
The Promise of Low Dose Naltrexone Therapy
EN NWISBN: 9780786452583 bzw. 0786452587, in Englisch, McFarland, neu.
Lieferung aus: Deutschland, sofort lieferbar.
2008, Englisch, Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.
2008, Englisch, Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers.
6
Elaine A. Moore, Dr. Yash P. Agrawal, Samantha Wilkinson, Dr. Yash P. Agrawal, Samantha Wilkinson, Foreword: Dr. Yash P. Agrawal, Collaborator: Samantha Wilkinson
The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (McFarland Health Topics) (2008)
EN NW EB DLISBN: 9780786452583 bzw. 0786452587, in Englisch, 223 Seiten, McFarland, neu, E-Book, elektronischer Download.
Lieferung aus: Vereinigte Staaten von Amerika, E-Book zum Download.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers. Kindle Edition, Format: Kindle eBook, Label: McFarland, McFarland, Produktgruppe: eBooks, Publiziert: 2008-12-01, Freigegeben: 2008-12-01, Studio: McFarland, Verkaufsrang: 315947.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers. Kindle Edition, Format: Kindle eBook, Label: McFarland, McFarland, Produktgruppe: eBooks, Publiziert: 2008-12-01, Freigegeben: 2008-12-01, Studio: McFarland, Verkaufsrang: 315947.
7
Elaine A. Moore, Dr. Yash P. Agrawal, Samantha Wilkinson, Dr. Yash P. Agrawal, Samantha Wilkinson, Vorwort: Dr. Yash P. Agrawal, Mitarbeiter: Samantha Wilkinson
The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (McFarland Health Topics) (2008)
EN NW EB DLISBN: 9780786452583 bzw. 0786452587, in Englisch, 223 Seiten, McFarland, neu, E-Book, elektronischer Download.
Lieferung aus: Deutschland, E-Book zum Download.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers. Kindle Edition, Format: Kindle eBook, Label: McFarland, McFarland, Produktgruppe: eBooks, Publiziert: 2008-12-01, Freigegeben: 2008-12-01, Studio: McFarland, Verkaufsrang: 171971.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 for opiate and drug abuse treatment. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, to reduce symptoms in multiple sclerosis and autism, and to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Grounded in clinical and scientific research, this book describes the history of naltrexone, its potential therapeutic uses, its effects on the immune system, its pharmacological properties, and how the drug is administered. It also lists fillers and compounding pharmacies, doctors who prescribe LDN, and patient resources, and includes interviews with LDN patients and researchers. Kindle Edition, Format: Kindle eBook, Label: McFarland, McFarland, Produktgruppe: eBooks, Publiziert: 2008-12-01, Freigegeben: 2008-12-01, Studio: McFarland, Verkaufsrang: 171971.
8
The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders
EN NW EB DLISBN: 9780786452583 bzw. 0786452587, in Englisch, McFarland & Company, Incorporated Publishers, McFarland & Company, Incorporated Publishers, McFarland & Company, Incorporated Publishers, neu, E-Book, elektronischer Download.
Lieferung aus: Vereinigte Staaten von Amerika, zzgl. Versandkosten, Free Shipping on eligible orders over $25.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, including pancreatic cancer, and to reduce symptoms in multiple sclerosis and autism. While ongoing clinical trials are evaluating the use of LDN in treating fibromyalgia and HIV/AIDS, it has been shown to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).Grounded in available clinical and scientific research, this book describes the history of naltrexone, including its potential therapeutic uses, its effects on the immune system, and its pharmacological properties. Aiming to acquaint readers with the potential therapeutic benefits of LDN, the book also includes practical chapters for those interested in its use, focusing on such topics as how the drug is administered, information on fillers and compounding pharmacies, lists of doctors who prescribe LDN, and available patient resources. It also features interviews with LDN patients and several of the country's top LDN researchers, who describe the importance of LDN in terms of its ability to provide relief from pain, halt disease progression, and facilitate the body's ability to heal. Finally, the work includes a useful glossary and an appendix listing important clinical trials completed to date, complete with researcher contact information and a summary of the trial outcomes.
Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, including pancreatic cancer, and to reduce symptoms in multiple sclerosis and autism. While ongoing clinical trials are evaluating the use of LDN in treating fibromyalgia and HIV/AIDS, it has been shown to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).Grounded in available clinical and scientific research, this book describes the history of naltrexone, including its potential therapeutic uses, its effects on the immune system, and its pharmacological properties. Aiming to acquaint readers with the potential therapeutic benefits of LDN, the book also includes practical chapters for those interested in its use, focusing on such topics as how the drug is administered, information on fillers and compounding pharmacies, lists of doctors who prescribe LDN, and available patient resources. It also features interviews with LDN patients and several of the country's top LDN researchers, who describe the importance of LDN in terms of its ability to provide relief from pain, halt disease progression, and facilitate the body's ability to heal. Finally, the work includes a useful glossary and an appendix listing important clinical trials completed to date, complete with researcher contact information and a summary of the trial outcomes.
9
Symbolbild
The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (1984)
EN PB NWISBN: 9780786437153 bzw. 0786437154, in Englisch, McFarland & Co Inc, Taschenbuch, neu.
Von Händler/Antiquariat, THE SAINT BOOKSTORE [51194787], Southport, MSY, United Kingdom.
BRAND NEW, The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders, Elaine A. Moore, Samantha Wilkinson, Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, including pancreatic cancer, and to reduce symptoms in multiple sclerosis and autism. While ongoing clinical trials are evaluating the use of LDN in treating fibromyalgia and HIV/AIDS, it has been shown to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).Grounded in available clinical and scientific research, this book describes the history of naltrexone, including its potential therapeutic uses, its effects on the immune system, and its pharmacological properties. Aiming to acquaint readers with the potential therapeutic benefits of LDN, the book also includes practical chapters for those interested in its use, focusing on such topics as how the drug is administered, information on fillers and compounding pharmacies, lists of doctors who prescribe LDN, and available patient resources. It also features interviews with LDN patients and several of the country's top LDN researchers, who describe the importance of LDN in terms of its ability to provide relief from pain, halt disease progression, and facilitate the body's ability to heal. Finally, the work includes a useful glossary and an appendix listing important clinical trials completed to date, complete with researcher contact information and a summary of the trial outcomes.
BRAND NEW, The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders, Elaine A. Moore, Samantha Wilkinson, Naltrexone is an opiate antagonist drug developed in the 1970s and approved by the FDA in 1984 as a safe and effective treatment for opiate and drug abuse. When used at much lower doses in an off-label protocol referred to as low dose naltrexone (LDN), the drug has been shown to halt disease progression in Crohn's disease and certain cancers, including pancreatic cancer, and to reduce symptoms in multiple sclerosis and autism. While ongoing clinical trials are evaluating the use of LDN in treating fibromyalgia and HIV/AIDS, it has been shown to improve numerous autoimmune and neurodegenerative conditions, including Parkinson's disease and amyotrophic lateral sclerosis (ALS).Grounded in available clinical and scientific research, this book describes the history of naltrexone, including its potential therapeutic uses, its effects on the immune system, and its pharmacological properties. Aiming to acquaint readers with the potential therapeutic benefits of LDN, the book also includes practical chapters for those interested in its use, focusing on such topics as how the drug is administered, information on fillers and compounding pharmacies, lists of doctors who prescribe LDN, and available patient resources. It also features interviews with LDN patients and several of the country's top LDN researchers, who describe the importance of LDN in terms of its ability to provide relief from pain, halt disease progression, and facilitate the body's ability to heal. Finally, the work includes a useful glossary and an appendix listing important clinical trials completed to date, complete with researcher contact information and a summary of the trial outcomes.
10
Symbolbild
The Promise Of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (2008)
EN PB NWISBN: 9780786437153 bzw. 0786437154, in Englisch, McFarland & Co Inc Pub, Taschenbuch, neu.
Von Händler/Antiquariat, Revaluation Books [2134736], Exeter, DEV, United Kingdom.
213 pages. 9.25x6.25x0.75 inches. In Stock.
213 pages. 9.25x6.25x0.75 inches. In Stock.
Lade…